XOMA’s (XOMA) Buy Rating Reaffirmed at HC Wainwright

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $74.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 192.03% from the stock’s current price.

Separately, SVB Leerink initiated coverage on shares of XOMA in a research note on Monday. They issued an “outperform” rating and a $40.00 price target on the stock.

XOMA Stock Down 4.4 %

Shares of XOMA stock opened at $25.34 on Wednesday. XOMA has a 52-week low of $13.48 and a 52-week high of $27.00. The company has a debt-to-equity ratio of 1.34, a quick ratio of 8.68 and a current ratio of 8.68. The stock has a market cap of $294.96 million, a price-to-earnings ratio of -6.27 and a beta of 0.58. The firm’s 50-day moving average is $25.04 and its 200-day moving average is $20.64.

XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). XOMA had a negative net margin of 886.91% and a negative return on equity of 25.17%. The business had revenue of $1.83 million during the quarter, compared to analyst estimates of $1.01 million. Sell-side analysts predict that XOMA will post -1.73 EPS for the current year.

Hedge Funds Weigh In On XOMA

An institutional investor recently raised its position in XOMA stock. Stonepine Capital Management LLC increased its holdings in XOMA Co. (NASDAQ:XOMA) by 25.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 436,602 shares of the biotechnology company’s stock after buying an additional 87,203 shares during the period. XOMA accounts for 2.0% of Stonepine Capital Management LLC’s holdings, making the stock its 12th largest position. Stonepine Capital Management LLC owned 3.80% of XOMA worth $6,152,000 as of its most recent SEC filing. 95.92% of the stock is owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.